Innovative Medicine

Study findings presented during the American College of Cardiology’s 72nd Annual Scientific Session & Expo Together With World Heart Federation’s World Congress of Cardiology European Society of Cardiology/European Respiratory Society (ESC/ERS) PH guidelines recommend initial dual combination therapy with macitentan and tadalafil for PAH patients without cardiopulmonary comorbidities

Findings presented at ACC.23 show XARELTO® plus aspirin provides a 33 percent reduction in acute limb ischemia following LER, with consistent benefit demonstrated at 30 days, 90 days and up to three years Patients who undergo LER are four times more likely to experience acute limb ischemia, which can lead to amputation or death if left untreated[i] XARELTO® is the first and only anticoagulant approved in combination with aspirin for reducing the risk of major thrombotic vascular events* in patients with peripheral artery disease (PAD)

Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ulcerative colitis achieved clinical remission, clinical response, and/or demonstrated endoscopic improvement at four years

Studies suggest mechanistic benefit of guselkumab by binding to cells that drive inflammation in the colon

That’s My Word™ campaign issues national call to action for earlier diagnosis and treatment to address the disproportionate impact of multiple myeloma among at-risk communities

Niraparib and Abiraterone Acetate Plus Prednisone Has Potential to Address Unmet Need for Patients with BRCA-Positive mCRPC

If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European Union for first-line treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations, when given with prednisone (P) or prednisolone.[i] The positive CHMP opinion is based on results from the Phase 3 MAGNITUDE study where the addition of niraparib to AA plus P significantly improved radiographic progression-free survival (rPFS) compared to standard of care in untreated mCRPC patients with BRCA1/2 mutations.[ii]

Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU

Updated data from the Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer will be featured